Literature DB >> 21236232

Evaluation of cross-protection between O1 Manisa and O1 Campos in cattle vaccinated with foot-and-mouth disease virus vaccine incorporating different payloads of inactivated O1 Manisa antigen.

Singanallur Balasubramanian Nagendrakumar1, Villuppanoor Alwar Srinivasan, Muthukrishnan Madhanmohan, Shanmugam Yuvaraj, Satya Parida, Antonello Di Nardo, Jacquelyn Horsington, David James Paton.   

Abstract

Serology is used to predict vaccine induced protection against challenge with a heterologous strain of the same serotype of foot-and-mouth disease virus (FMDV). To evaluate the accuracy of such predictions, we compared the protection afforded to cattle vaccinated with the O(1) Manisa strain of FMDV against challenge with either a homologous (O(1) Manisa) or a heterologous strain (O(1) Campos). Serology by virus neutralization test (VNT) using O(1) Manisa antiserum predicted an acceptable protection against such a challenge. Two experiments were carried out to compare the results for consistency. A total of 78 naïve cattle were vaccinated with different antigen payloads (60-0.94 μg) of O(1) Manisa. They were challenged by intradermolingual inoculation with live FMDV, either O(1) Manisa or O(1) Campos. Unvaccinated naïve control cattle (n=20) were also challenged with either the O(1) Manisa or O(1) Campos viruses and all developed generalized FMD. The protection results for the vaccinated cattle revealed that higher payloads of O(1) Manisa vaccine were needed to protect against heterologous challenge compared to that for homologous challenge. The 50% protective dose (PD(50)) values for the vaccine in experiments 1 and 2 were found to be 28.78 and 9.44 for the homologous challenge and 3.98 and 5.01 for heterologous challenge. Furthermore, protection against O(1) Campos required a higher level of vaccine-induced antibody against this virus compared to the level of O(1) Manisa neutralizing antibody associated with protection against homologous challenge. The 50% protective level of in vitro neutralizing antibody was found to be log(10)1.827 for O(1) Campos and log(10)0.954 for O(1) Manisa based on O(1) Manisa based virus neutralization test.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21236232     DOI: 10.1016/j.vaccine.2010.12.127

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Comparison of test methodologies for foot-and-mouth disease virus serotype A vaccine matching.

Authors:  Tesfaalem Tekleghiorghis; Klaas Weerdmeester; Froukje van Hemert-Kluitenberg; Rob J M Moormann; Aldo Dekker
Journal:  Clin Vaccine Immunol       Date:  2014-03-12

2.  Supplementation of dietary germanium biotite enhances induction of the immune responses by foot-and-mouth disease vaccine in cattle.

Authors:  Myunghwan Jung; Min-Kyoung Shin; Seung-Bin Cha; Seung Won Shin; Anna Yoo; Won-Jung Lee; Hong-Tae Park; Jong-Hyeon Park; Byounghan Kim; Yeon-Kwon Jung; Han Sang Yoo
Journal:  BMC Vet Res       Date:  2014-08-12       Impact factor: 2.741

3.  The protective capacity of high payload FMDV A22 IRQ vaccine in sheep against direct-contact challenge with a heterologous, contemporary FMDV A strain from South East Asia.

Authors:  Jacquelyn Horsington; Charles Nfon; Hilary Bittner; Peter A Durr; Nagendrakumar Singanallur; Soren Alexandersen; Wilna Vosloo
Journal:  PLoS One       Date:  2018-06-18       Impact factor: 3.240

4.  Evaluation of immunogenicity and cross-reactive responses of  vaccines prepared from two chimeric serotype O foot-and-mouth disease viruses in pigs and cattle.

Authors:  Pinghua Li; Shulun Huang; Jingjing Zha; Pun Sun; Dong Li; Huifang Bao; Yimei Cao; Xingwen Bai; Yuanfang Fu; Xueqing Ma; Kun Li; Hong Yuan; Jing Zhang; Zhixun Zhao; Jian Wang; Keqiang Zhang; Yingli Chen; Qiang Zhang; Shuyun Qi; Zaixin Liu; Zengjun Lu
Journal:  Vet Res       Date:  2022-07-08       Impact factor: 3.829

5.  Assessment on Different Vaccine Formulation Parameters in the Protection against Heterologous Challenge with FMDV in Cattle.

Authors:  Sebastián Di Giacomo; Danilo Bucafusco; Juan Manuel Schammas; Juan Pega; María Cruz Miraglia; Florencia Barrionuevo; Alejandra Victoria Capozzo; Daniel Mariano Perez-Filgueira
Journal:  Viruses       Date:  2022-08-15       Impact factor: 5.818

6.  Characterization of monoclonal antibodies against foot-and-mouth disease virus serotype O and application in identification of antigenic variation in relation to vaccine strain selection.

Authors:  Ming Yang; Wanhong Xu; Melissa Goolia; Zhidong Zhang
Journal:  Virol J       Date:  2014-08-01       Impact factor: 4.099

7.  Genetic and antigenic characterization of serotype O FMD viruses from East Africa for the selection of suitable vaccine strain.

Authors:  Katie Lloyd-Jones; Mana Mahapatra; Sasmita Upadhyaya; David J Paton; Aravindh Babu; Geoff Hutchings; Satya Parida
Journal:  Vaccine       Date:  2017-12-14       Impact factor: 3.641

8.  Rapid Engineering of Foot-and-Mouth Disease Vaccine and Challenge Viruses.

Authors:  Seo-Yong Lee; Yeo-Joo Lee; Rae-Hyung Kim; Jeong-Nam Park; Min-Eun Park; Mi-Kyeong Ko; Joo-Hyung Choi; Jia-Qi Chu; Kwang-Nyeong Lee; Su-Mi Kim; Dongseob Tark; Hyang-Sim Lee; Young-Joon Ko; Min-Goo Seo; Jung-Won Park; Byounghan Kim; Myoung-Heon Lee; Jong-Soo Lee; Jong-Hyeon Park
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

9.  Cross-Protection Induced by a A/MAY/97 Emergency Vaccine Against Intra-Serotype Heterologous Challenge with a Foot-and-Mouth Disease Virus from the A/ASIA/G-VII Lineage.

Authors:  Aldo Dekker; Beatriz Sanz-Bernardo; Nagendrakumar Balasubramanian Singanallur; Anna B Ludi; Jacquelyn Horsington; Phaedra L Eblé; Donald P King; Wilna Vosloo
Journal:  Vaccines (Basel)       Date:  2020-01-14

10.  Molecular Basis of Antigenic Drift in Serotype O Foot-and-Mouth Disease Viruses (2013-2018) from Southeast Asia.

Authors:  Sasmita Upadhyaya; Mana Mahapatra; Valerie Mioulet; Satya Parida
Journal:  Viruses       Date:  2021-09-21       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.